Psychopharmacology

Serum drug levels provide crucial insights for optimizing psychiatric treatment, enhancing patient outcomes in cases of schizophrenia and OCD.

Benzodiazepines spark ongoing debate, balancing effective anxiety relief with addiction risks, as cultural attitudes shape their use and perception.

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Valproic acid poses significant risks during pregnancy, including congenital malformations and neurodevelopmental disorders, necessitating careful treatment planning.

New analysis qualifies OPTIMUM study, finding antidepressant combinations more effective than switching for treatment resistant depression in elderly.

In this CME article, discover effective strategies for prescribing MAOIs in treating major depressive disorder.

Debate over using SSRIs in pregnancy in recent FDA focus group raises questions, despite extensive research supporting SSRI use for maternal mental health.

Gus Alva, MD, discusses the FDA committee vote on brexpiprazole for PTSD, what it means, and what's next.

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

Learn more about how serum drug levels enhance psychiatric treatment by providing critical insights into medication efficacy and patient outcomes.

How can we teach psychopharmacology in a way that engages today's digital-native psychiatry residents and enhances real-world application?

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Roger S. McIntyre, MD, FRCPC, shares the backstory and pharmacology of incretins to better understand the role of GLP-1 RAs in psychiatry.

Sara Robinson, DNP, RN, PMHNP-BC, provides insight on considerations surrounding prescribing psychiatric medications for perinatal patients.

Rebecca Barbee, PA-C, shares tips on addressing the heat wave and its implications when talking with patients.

Learn more about how to best assess and treat tardive dyskinesia.

Now more than ever, capturing and scaling the ingredients that make for compelling and impactful teaching for trainees is vital to our future.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.

Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.